Treatment Gap
Most patients were eligible for GDMT, but prescribing was much lower. The study defined the treatment gap as the share of eligible patients who were not prescribed the relevant therapy at discharge. In 2022, only 29% of eligible patients r…
1 sources - 5 claims
Most patients were eligible for GDMT, but prescribing was much lower. The study defined the treatment gap as the share of eligible patients who were not prescribed the relevant therapy at discharge. In 2022, only 29% of eligible patients received quadruple therapy at discharge, leaving a 71% treatment gap. Underuse of quadruple therapy persisted even after excluding patients with relative cautions as well as contraindications. About 7% of the cohort was discharged without any foundational GDMT drug.